PT - JOURNAL ARTICLE AU - Kachuri, Linda AU - Francis, Stephen S. AU - Morrison, Maike AU - Cavazos, Taylor B. AU - Rashkin, Sara R. AU - Ziv, Elad AU - Witte, John S. TI - The landscape of host genetic factors involved in infection to common viruses and SARS-CoV-2 AID - 10.1101/2020.05.01.20088054 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.01.20088054 4099 - http://medrxiv.org/content/early/2020/05/07/2020.05.01.20088054.short 4100 - http://medrxiv.org/content/early/2020/05/07/2020.05.01.20088054.full AB - Humans and viruses have co-evolved for millennia resulting in genetic polymorphisms that affect response to viral infection. We conducted a comprehensive study in the UK biobank linking germline genetic variation and gene expression with 28 antigens for 16 viruses in 7924 subjects. We discovered 7 novel loci associated with antibody response (P<5.0×10−8), including FUT2 for human polyomavirus BKV, TMEM173 for Merkel cell polyomavirus (MCV), and TBKBP1 for human herpesvirus 7. Transcriptome-wide analyses identified 114 genes association with response to viral infection, including ECSCR: P=5.0×10−15 (MCV), NTN5: P=1.1×10−9 (BKV), and P2RY13: P=1.1×10−8 (Epstein-Barr virus nuclear antigen). Signals in human leukocyte antigen (HLA) class II region dominated the landscape of viral antibody response, with 40 independent loci and 14 independent classical alleles, 7 of which exhibited pleiotropic effects across viral families. We also link viral response genes with complex diseases, such as C4A expression in varicella zoster virus and schizophrenia. Lastly, based on 1028 subjects tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we identify 7 class II HLA susceptibility alleles (5 associated with other viruses). We also observe that genetic determinants of ACE2 expression may influence SARS-CoV-2 susceptibility. Our findings elucidate the genetic architecture of host response to viral infection, with potential implications for complex diseases and COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by funding from the National Institutes of Health (US NCI R25T CA112355 and R01 CA201358; PI: Witte). Maike Morrison was funded by the University of California San Francisco’s Amgen Scholars Program.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe UK Biobank in an open access resource, available at https://www.ukbiobank.ac.uk/researchers/. This research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte).